AR117006A1 - Compuesto de 1,3-azol sustituido, composición farmacéutica que lo comprende y su uso para la fabricación de un medicamento - Google Patents

Compuesto de 1,3-azol sustituido, composición farmacéutica que lo comprende y su uso para la fabricación de un medicamento

Info

Publication number
AR117006A1
AR117006A1 ARP190103251A ARP190103251A AR117006A1 AR 117006 A1 AR117006 A1 AR 117006A1 AR P190103251 A ARP190103251 A AR P190103251A AR P190103251 A ARP190103251 A AR P190103251A AR 117006 A1 AR117006 A1 AR 117006A1
Authority
AR
Argentina
Prior art keywords
fluoro
independently selected
substituents independently
substituted
alkyl
Prior art date
Application number
ARP190103251A
Other languages
English (en)
Inventor
Jr Terrence L Smalley
Christie Schulte
Andrew L Larkin
David Norman Deaton
Rodolfo Cadilla
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of AR117006A1 publication Critical patent/AR117006A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D421/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms
    • C07D421/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms containing two hetero rings
    • C07D421/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un compuesto de fórmula (1) en donde Ar¹, R²¹, R²³, R²⁴, R²⁵, R²⁶, R²⁷, A, X, Y y W son como se definen en el presente documento. Los compuestos de la presente son inhibidores de prostaglandina D sintasa hematopoyética (H-PGDS) y pueden ser útiles en el tratamiento de distrofia muscular de Duchenne. Por consiguiente, la presente se refiere además a composiciones farmacéuticas que comprenden un compuesto de la misma. La presente también se refiere además a métodos para inhibir la actividad de H-PGDS y tratamiento de trastornos asociados a la misma usando un compuesto de la presente o una composición farmacéutica que comprende un compuesto de la presente. Reivindicación 1: Un compuesto de 1,3-azol sustituido caracterizado porque tiene la fórmula (1), en donde: Ar¹ se selecciona entre: fenilo, benzofuranilo, pirazolilo, imidazolilo, piridinilo, y pirimidinilo, cada uno de los cuales está opcionalmente sustituido con 1 a 4 sustituyentes seleccionados independientemente entre: fluoro, cloro, bromo, yodo, alquilo C₁₋₃, alquilo C₁₋₃ sustituido con uno a cuatro sustituyentes seleccionados independientemente entre: -OH, oxo y fluoro, -CN, -OH, ciclopropilo, alcoxi C₁₋₃, y alcoxi C₁₋₃ sustituido con uno a cuatro sustituyentes seleccionados independientemente entre: -OH, oxo y fluoro; W se selecciona entre: S y Se; X se selecciona entre: C y N; Y se selecciona entre: -C(O)-, -C(S)-, -C(Se)-, -S(O)- y -S(O₂)-; A se selecciona entre: -C(O)-, -C(S)-, -C(Se)- y -S(O₂)-; R²¹ se selecciona entre: hidrógeno y -CH₃; R²³ y R²⁴ están unidos a átomos de carbono iguales o diferentes y se seleccionan independientemente entre: hidrógeno, alquilo C₁₋₅, alquilo C₁₋₅ sustituido con uno o cuatro sustituyentes independientemente seleccionados entre: -OH, oxo, -NH₂ y fluoro, o R²³ y R²⁴ están unidos al mismo carbono y se toman juntos para formar: ciclopropilo, ciclobutilo, ciclopentilo, oxetanilo, tetrahidrofurano, o tetrahidropirano, o R²³ y R²⁴ están unidos a diferentes átomos de carbono y se toman juntos para formar: ciclopropilo, ciclobutilo, ciclopentilo, oxetanilo, tetrahidrofurano, o tetrahidropirano; R²⁵ se selecciona entre: hidrógeno, alquilo C₁₋₅, alquilo C₁₋₅ sustituido con uno a cuatro sustituyentes independientemente seleccionados entre: -OH, oxo, -NH₂ y fluoro, y alquilarilo C₁₋₅, y alquilarilo C₁₋₅ sustituido con 1 a 3 sustituyentes independientemente seleccionados entre fluoro, cloro, bromo, yodo, alquilo C₁₋₃, alquilo C₁₋₃ sustituido con uno a cuatro sustituyentes independientemente seleccionados entre: -OH, oxo y fluoro, -CN, -OH, ciclopropilo, alcoxi C₁₋₃, y alcoxi C₁₋₃ sustituido con uno a cuatro sustituyentes independientemente seleccionados entre: -OH, oxo y fluoro; R²⁶ se selecciona entre: hidrógeno y -CH₃; y R²⁷ está ausente cuando X es N o se selecciona entre: hidrógeno y -CH₃; o una sal farmacéuticamente aceptable del mismo.
ARP190103251A 2018-11-08 2019-11-06 Compuesto de 1,3-azol sustituido, composición farmacéutica que lo comprende y su uso para la fabricación de un medicamento AR117006A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862757205P 2018-11-08 2018-11-08

Publications (1)

Publication Number Publication Date
AR117006A1 true AR117006A1 (es) 2021-07-07

Family

ID=68542702

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190103251A AR117006A1 (es) 2018-11-08 2019-11-06 Compuesto de 1,3-azol sustituido, composición farmacéutica que lo comprende y su uso para la fabricación de un medicamento

Country Status (10)

Country Link
US (1) US20220009918A1 (es)
EP (1) EP3877384A1 (es)
JP (1) JP2022506850A (es)
CN (1) CN112969698A (es)
AR (1) AR117006A1 (es)
BR (1) BR112021008976A2 (es)
CA (1) CA3117943A1 (es)
TW (1) TW202039479A (es)
UY (1) UY38455A (es)
WO (1) WO2020095215A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230339937A1 (en) 2020-06-19 2023-10-26 Sato Pharmaceutical Co., Ltd. Condensed ring compounds that inhibit h-pgds

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6576265B1 (en) 1999-12-22 2003-06-10 Acell, Inc. Tissue regenerative composition, method of making, and method of use thereof
WO2005094805A1 (ja) 2004-04-01 2005-10-13 Institute Of Medicinal Molecular Design. Inc. イミン誘導体及びアミド誘導体
TW200720255A (en) 2005-07-13 2007-06-01 Taiho Pharmaceutical Co Ltd Benzoimidazole compound capable of inhibiting prostaglandin d synthetase
JP2007051121A (ja) 2005-07-22 2007-03-01 Taiho Yakuhin Kogyo Kk プロスタグランジンｄ合成酵素を阻害するピリミジン化合物
PE20110118A1 (es) 2005-10-04 2011-03-08 Aventis Pharma Inc Compuestos de pirimidina amida como inhibidores de pgds
JP2010513458A (ja) 2006-12-19 2010-04-30 ファイザー・プロダクツ・インク Ｈ−ｐｇｄｓの阻害剤としてのニコチンアミド誘導体、およびプロスタグランジンｄ２の仲介による疾患を治療するためのその使用
MY154895A (en) 2007-03-30 2015-08-14 Sanofi Aventis Pyrimidine hydrazide compounds as pgds inhibitors
GB0706793D0 (en) 2007-04-05 2007-05-16 Evotec Ag Compounds
CN102015656A (zh) 2008-04-28 2011-04-13 旭化成制药株式会社 苯丙酸衍生物及其用途
AU2009246446B2 (en) 2008-05-13 2014-06-26 Cayman Chemical Company, Incorporated Methods for assaying compounds or agents for ability to displace potent ligands of hematopoietic prostaglandin D synthase
US20110306597A1 (en) 2008-06-18 2011-12-15 James Michael Crawforth Nicotinamide Derivatives
CA2724998A1 (en) 2008-06-18 2009-12-23 Pfizer Limited Nicotinamide derivatives
WO2010033977A2 (en) 2008-09-22 2010-03-25 Cayman Chemical Company Multiheteroaryl compounds as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
SG173865A1 (en) 2009-03-09 2011-09-29 Taiho Pharmaceutical Co Ltd Piperazine compound capable of inhibiting prostaglandin d synthase
EP2487175A1 (en) 2009-10-06 2012-08-15 Kyowa Hakko Kirin Co., Ltd. Pharmaceutical product containing aromatic heterocyclic compound
MX2012003021A (es) 2009-10-08 2012-04-10 Sanofi Sa Derivados de feniloxadiazol como agentes inhibidores de las pgds.
MY161134A (en) 2010-01-22 2017-04-14 Taiho Pharmaceutical Co Ltd Piperazine compound having a pgds inhibitory effect
TW201326154A (zh) 2011-11-28 2013-07-01 拜耳知識產權公司 作為ｅｐ２受體拮抗劑之新穎２ｈ－吲唑
WO2018229629A1 (en) * 2017-06-13 2018-12-20 Glaxosmithkline Intellectual Property Development Limited Chemical compounds as h-pgds inhibitors

Also Published As

Publication number Publication date
EP3877384A1 (en) 2021-09-15
CN112969698A (zh) 2021-06-15
JP2022506850A (ja) 2022-01-17
UY38455A (es) 2020-05-29
US20220009918A1 (en) 2022-01-13
BR112021008976A2 (pt) 2021-08-03
CA3117943A1 (en) 2020-05-14
TW202039479A (zh) 2020-11-01
WO2020095215A1 (en) 2020-05-14

Similar Documents

Publication Publication Date Title
MX2022010520A (es) Macrociclos peptidicos contra acinetobacter baumannii.
AR109788A1 (es) Compuestos de benzo[b]tiofeno como agonistas de sting
AR109315A1 (es) Composiciones farmacéuticas que contienen derivados de piridona policíclica sustituida y profármaco de las mismas
AR109905A1 (es) Pirrolidinas sustituidas como moduladores de cftr
PE20160126A1 (es) Derivados del bipirazol como inhibidores jak
CL2020001343A1 (es) Nuevos profármacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson.
NZ708593A (en) Novel pyrazole derivative
BR112015021983A2 (pt) compostos heterocíclicos e usos dos mesmos
MX2015017861A (es) Derivados de benzotiofeno como inhibidores del receptor de estrogeno.
AR106865A1 (es) Piridinas sustituidas y métodos de uso
AR095426A1 (es) Inhibidores tripeptídicos de la epoxicetona proteasa
AR091093A1 (es) Tienopirimidinas
JP2017514910A5 (es)
PH12016501977A1 (en) 2-AMINO-6-METHYL-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL-1,3-THIAZOL-4-YL AMIDES
EA201401082A1 (ru) Фармацевтические препараты, содержащие антагонисты ccr3
BR112020020768A2 (pt) Derivados de pirazol-triazina e/ou pirazol-pirimidina como inibidor seletivo de cinase dependente de ciclina
IN2013MU03577A (es)
HRP20220429T1 (hr) Novi antagonisti receptora bradikinina b2
AR111494A1 (es) Compuestos de anilinoquinazolina c₅ y su uso en el tratamiento del cáncer
AR110241A1 (es) Ácidos indanilaminopiridil-ciclopropano-carboxílicos, composiciones farmacéuticas y usos de los mismos
PH12017502254B1 (en) Pyrazole derivative or pharmaceutically acceptable salt thereof
PH12019500822A1 (en) Crystalline forms of eravacycline
CL2018000839A1 (es) Derivados de 2-aminoquinazolina como inhibidores de la quinasa p70s6
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
AR117006A1 (es) Compuesto de 1,3-azol sustituido, composición farmacéutica que lo comprende y su uso para la fabricación de un medicamento